BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Gong CL, Hitchcock MM, Holubar M, Deresinski S, Hay JW. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00187-7. [PMID: 33878506 DOI: 10.1016/j.cmi.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wingen-Heimann SM, van Prehn J, Kuijper EJ, Vehreschild MJGT. The need for a holistic view on management of Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00406-7. [PMID: 34311078 DOI: 10.1016/j.cmi.2021.07.014] [Reference Citation Analysis]
2 Marcela K, de Meij GT, Fidelma F, Richard DJ, Mark WH, Ed KJ. How to: Clostridioides difficile infection in children. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.03.001] [Reference Citation Analysis]
3 Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Reference Citation Analysis]
4 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]